Baze’s at-home blood testing kits assess consumers’ blood nutrient status, which Baze then analyzes using its Nutrition Information System to offer nutrition plans and curate supplement subscriptions.
PRNewsfoto/Baze
Baze (Boston, MA), a personalized nutrition company, received approval from the U.S. Food and Drug Administration for its at-home blood collection process. Baze’s at-home blood testing kits assess consumers’ blood nutrient status, which Baze then analyzes using its Nutrition Information System to offer nutrition plans and supplement subscriptions specifically curated for individual customers’ needs and deficiencies. The patented Nutrition Information System is a proprietary analytics platform that maps an individual’s nutrient levels against leading research to determine their idea supplement regimen.
"Our evidence-based approach has been a cornerstone of our development," said Philipp Schulte, co-Founder and CEO of Baze, in a press release. "The FDA's approval of our blood collection kit further reinforces that commitment to science, compliance, and safety. This will allow even more people to quickly and conveniently assess their nutrient deficiencies within their homes, without the hassle and cost of unnecessary trips to the doctor. This is a game-changer for the future of Baze, and, more importantly, for the future of personalized nutrition."
In August of 2019, Baze raised $6 million in Series A funding led by Nature’s Way, which the firm has used to expand its executive team, and broaden its nutrient panel, deepen its data analytics, and begin exploratory work with partner-driven food subscription programs.
"Nutrition is the foundational aspect of everyone's health," said Allison Baker, vice president of business development for Baze, in a press release. "Yet managing nutrition is currently the largest black-box in our healthcare system. Gaining regulatory approval for our approach is a huge step in allowing us to shine a light on what nutrients people actually need. Healthcare is deeply personal, and through our expanded reach we will be able to help many more people make informed, personalized choices with their food and supplement regimen."
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.